MARKET

MRNS

MRNS

Marinus Pharmace
NASDAQ
1.410
+0.040
+2.92%
After Hours: 1.440 +0.03 +2.13% 19:51 07/15 EDT
OPEN
1.390
PREV CLOSE
1.370
HIGH
1.420
LOW
1.370
VOLUME
669.40K
TURNOVER
0
52 WEEK HIGH
11.26
52 WEEK LOW
1.100
MARKET CAP
77.46M
P/E (TTM)
-0.5349
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MRNS last week (0708-0712)?
Weekly Report · 11h ago
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Such investors are advised to contact Danielle Peyton at pomerantzlawyers@pomerantzllp.com The class action is on behalf of Marinus shareholders.
Barchart · 5d ago
Weekly Report: what happened at MRNS last week (0701-0705)?
Weekly Report · 07/08 11:59
Weekly Report: what happened at MRNS last week (0624-0628)?
Weekly Report · 07/01 11:59
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Barchart · 07/01 04:45
Wednesday's ETF with Unusual Volume: XPH
NASDAQ · 06/26 16:31
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More
TipRanks · 06/25 18:35
Weekly Report: what happened at MRNS last week (0617-0621)?
Weekly Report · 06/24 12:09
More
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Webull offers Marinus Pharmaceuticals Inc stock information, including NASDAQ: MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.